Mankind Pharma Approves Raising Rs 10,000 Crore Via NCDs, CPs
Mankind Pharma Ltd.'s board has approved raising up to Rs 10,000 crore through non-convertible debentures and commercial papers. The board has approved raising up to Rs 5,000 crore via NCDs and Rs 5,000 crore via commercial papers, according to an exchange filing on Monday.
The company will issue secured, rated, and listed NCDs, denominated in amounts up to Rs 5 lakh with a nominal value of Rs 1 lakh each, totaling a maximum of Rs 50,000 crore. The company will offer these NCDs in 3-4 distinct series, with maturities extending up to 48 months or four years.
Additionally, the company plans to issue listed and rated commercial papers, with the face value determined in accordance with applicable laws. The company will issue these commercial papers in one or more series, with a total financing amount not exceeding Rs 50,000 crore.
Earlier on Sept. 24, India's fourth-largest pharmaceutical company's Vice Chairman and Managing Director Rajeev Juneja told NDTV Profit that the company will raise Rs 7,000 crore debt to fund its acquisition of Bharat Serums and Vaccines Ltd.
In July this year, the pharma major announced plans to acquire 100% stake in Bharat Serums and Vaccines from private equity firm Advent International for Rs 13,630 crore to expand its footprint in the specialty pharma sector.
“Out of this approximately Rs 14,000 crore deal, Rs 4,000 crore will be coming from the company side. Of the remaining Rs 10,000 crore, Rs 3,000 crore will be coming from the QIP (qualified institutional placement), and the rest will be funded through debt," Juneja SAID.
Shares of Mankind Pharma were trading 1.12% lower at Rs 2,562.85 apiece, compared to a 1.11% decline in the benchmark Nifty 50 as of 12:54 p.m.
It has fallen 43.64% in the last 12 months but has risen 30.10% on a year-to-date basis. The relative strength index was at 69.22.
Twelve out of the 16 analysts tracking the company have a 'buy' rating on the stock, three recommend a 'hold rating, and one suggests a 'sell', according to Bloomberg data. The average of 12-month analyst price targets implies a potential downside of 5.2%.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
